Kondili, LA, Romano, F, Rolli, FR, Ruggeri, M, Rosato, S, Brunetto, MR, Zignego, AL, Ciancio, A, Di Leo, A, Raimondo, G, Ferrari, C, Taliani, G, Borgia, G, Santantonio, TA, Blanc, P, Gaeta, GB
, Gasbarrini, A, Chessa, L, Erne, EM, Villa, E, Ieluzzi, D, Russo, FP, Andreone, P, Vinci, M, Coppola, C, Chemello, L, Madonia, S, Verucchi, G, Persico, M, Zuin, M, Puoti, M, Alberti, A, Nardone, G, Massari, M, Montalto, G, Foti, G, Rumi, MG, Quaranta, MG
, Cicchetti, A, Craxì, A & Vella, S 2017, '
Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort',
Hepatology, n. n/a, pagg. N/A-N/A.
https://doi.org/10.1002/hep.29399